CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma. [electronic resource]
Producer: 20160608Description: 621-9 p. digitalISSN:- 1873-7560
- ATP Binding Cassette Transporter, Subfamily B -- genetics
- Aged
- Antineoplastic Agents -- adverse effects
- Carcinoma, Renal Cell -- drug therapy
- Cytochrome P-450 CYP3A -- genetics
- Disease Progression
- Disease-Free Survival
- Female
- Haplotypes
- Humans
- Indoles -- adverse effects
- Kaplan-Meier Estimate
- Kidney Neoplasms -- drug therapy
- Male
- Middle Aged
- Netherlands
- Ohio
- Pharmacogenetics
- Polymorphism, Single Nucleotide
- Proportional Hazards Models
- Protein Kinase Inhibitors -- adverse effects
- Pyrroles -- adverse effects
- Risk Factors
- Spain
- Sunitinib
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.